Gregory M. Torre
Keine laufenden Positionen mehr
Profil
Gregory M.
Torre formerly worked at SELLAS Life Sciences Group, Inc., as Director, Chief Regulatory Officer & Senior VP from 2017 to 2018, NPS Pharmaceuticals, Inc., as Senior Vice President-Regulatory Affairs from 2006 to 2007, and Elusys Therapeutics, Inc., as Vice President-Drug Development.
Dr. Torre received his doctorate degree from St. John's University and graduate degree from Brooklyn Law School.
Ehemalige bekannte Positionen von Gregory M. Torre
| Unternehmen | Position | Ende |
|---|---|---|
| SELLAS LIFE SCIENCES GROUP, INC. | Chief Tech/Sci/R&D Officer | 27.04.2018 |
| NPS PHARMACEUTICALS, INC. | General Counsel | 31.07.2007 |
Elusys Therapeutics, Inc.
 Elusys Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Elusys Therapeutics, Inc. develops antibody therapies. It is engaged in development Anthim (oblitoxaximab) a mAb anthrax antitoxin for the treatment and prevention of inhalational anthrax used in a bioterror attack. The company was founded in May 1998 and is headquartered in Pine Brook, NJ. | General Counsel | - |
Ausbildung von Gregory M. Torre
| St. John's University | Doctorate Degree |
| Brooklyn Law School | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| SELLAS LIFE SCIENCES GROUP, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
NPS Pharmaceuticals, Inc.
 NPS Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology NPS Pharmaceuticals, Inc. developed drugs for bone and mineral disorders. It also developed Natpara for the treatment of adult hypoparathyroidism. The company was founded by Hunter Jackson and Thomas N. Parks on October 22, 1986 and is headquartered in Bedminster, NJ. | Health Technology |
Elusys Therapeutics, Inc.
Elusys Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Elusys Therapeutics, Inc. develops antibody therapies. It is engaged in development Anthim (oblitoxaximab) a mAb anthrax antitoxin for the treatment and prevention of inhalational anthrax used in a bioterror attack. The company was founded in May 1998 and is headquartered in Pine Brook, NJ. | Health Technology |
